Abstract
AbstractTolerogenic dendritic cells (tDCs) induces regulatory T cell (Treg) differentiation and promotes immune tolerance. However, the effective generation of tDCs in vivo to treat autoimmune diseases remains a significant challenge. In this study, the potential of 1α, 25‐Dihydroxyvitamin D3 (VD3) is explored, which has been shown to promote tDCs differentiation in vitro, to induce tDCs in a mouse model of experimental autoimmune encephalomyelitis (EAE). To overcome the poor solubility of VD3 and induce autoantigen‐specific Tregs, a PLGA‐PEG‐based nano‐drug delivery system is prepared to co‐deliver VD3 and myelin‐oligodendrocyte glycoprotein (MOG) peptides. It is found that intradermal (i.d.) injection of NP/VD3/MOG significantly enhanced the level of antigen‐specific Tregs in vivo. Furthermore, NP/VD3/MOG remarkedly delayed the onset, reduced the severity, and promoted the recovery of EAE mice. This study provides an effective strategy for the treatment of autoimmune diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
